These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Clinical characteristics and prognosis of hepatocellular carcinoma with different sets of serum AFP and PIVKA-II levels. Kang SH; Kim DY; Jeon SM; Ahn SH; Park JY; Kim SU; Kim JK; Lee KS; Chon CY; Han KH Eur J Gastroenterol Hepatol; 2012 Jul; 24(7):849-56. PubMed ID: 22495400 [TBL] [Abstract][Full Text] [Related]
10. [Clinical characteristics of hepatocellular carcinoma in patients with antibody to hepatitis C virus]. Nagoshi S; Fujiwara K Nihon Rinsho; 2004 Jul; 62 Suppl 7(Pt 1):615-8. PubMed ID: 15359871 [No Abstract] [Full Text] [Related]
11. Ultrasound-guided fine needle biopsy of intrahepatic nodules and low elevation of AFP in early diagnosis of hepatocellular carcinoma. He YM; Wang XY; Gao SD; Yu LY; Lin XD; Lin LW Hepatobiliary Pancreat Dis Int; 2005 Feb; 4(1):50-4. PubMed ID: 15730919 [TBL] [Abstract][Full Text] [Related]
12. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma]. Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968 [TBL] [Abstract][Full Text] [Related]
13. [Treatment of hepatocellular carcinoma in the cirrhotic liver]. Hourmand-Ollivier I; Chiche L J Chir (Paris); 2004 Mar; 141(2):71-83. PubMed ID: 15133430 [TBL] [Abstract][Full Text] [Related]
14. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy. Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841 [TBL] [Abstract][Full Text] [Related]
15. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma. Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021 [TBL] [Abstract][Full Text] [Related]
16. Time courses of PIVKA-II and AFP levels after hepatic artery embolization and hepatic artery infusion against hepatocellular carcinoma: relation between the time course and tumor necrosis. Kishi K; Sonomura T; Mitsuzane K; Nishida N; Kimura M; Satoh M; Yamada R; Kodama N; Kinoshita M; Tanaka H Radiat Med; 1992; 10(5):189-95. PubMed ID: 1279748 [TBL] [Abstract][Full Text] [Related]
17. [Imaging techniques in hepatocellular carcinoma: diagnosis, extension and evaluation of therapeutic response]. Ayuso C; Rimola J; Forner A Gastroenterol Hepatol; 2010 Dec; 33(10):721-6. PubMed ID: 20447736 [TBL] [Abstract][Full Text] [Related]
18. [Role of magnetic resonance in the follow-up o hepatocarcinoma treated with percutaneous ethanol injection (PEI) or transarterial chemoembolization (TACE)]. De Cobelli F; Castrucci M; Sironi S; Livraghi T; Venturini M; Salvioni M; Del Maschio A Radiol Med; 1994 Dec; 88(6):806-17. PubMed ID: 7878241 [TBL] [Abstract][Full Text] [Related]
20. Prognostic values of alpha-fetoprotein and protein induced by vitamin K absence or antagonist-II in hepatitis B virus-related hepatocellular carcinoma: a prospective study. Kim HS; Park JW; Jang JS; Kim HJ; Shin WG; Kim KH; Lee JH; Kim HY; Jang MK J Clin Gastroenterol; 2009; 43(5):482-8. PubMed ID: 19197197 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]